NCT03276832 2026-03-19
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
Clinical Trials
37 trialsNCT03534947 2025-12-16
SONIB
Melanoma Institute Australia
Phase 2 Completed
NCT04883645 2025-01-28
Neoadjuvant Imiquimod Immunotherapy for Oral Cancer
Medical University of South Carolina
Phase EARLY_PHASE1 Completed
NCT01803152 2024-07-03
Dendritic Cell Vaccine for Children and Adults With Sarcoma
University of Miami
Phase 1 Completed
NCT02394132 2024-06-20
RADICAL
Melanoma and Skin Cancer Trials Limited
Phase 3 Completed
NCT02864147 2024-05-02
Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)
Yale University
Phase 2 Completed
NCT03559413 2023-12-04
Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL
University Children's Hospital Tuebingen
Phase 1/2 Completed
NCT00788164 2023-08-31
Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00314756 2023-08-22
Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage
Wake Forest University Health Sciences
Phase 4 Completed
NCT02802943 2022-11-28
iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL
University Hospital Tuebingen
Phase 2 Completed
NCT00142454 2022-10-10
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT01808820 2022-07-20
Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma
University of Miami
Phase 1 Completed
NCT04842422 2022-01-11
Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream
Medical University of Graz
Phase 4 Completed
NCT01421017 2021-11-18
Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases
NYU Langone Health
Phase 1/2 Completed
NCT01861535 2021-04-14
PITVIN
Medical University of Graz
Phase 3 Completed
NCT03233412 2021-02-17
Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions
Barretos Cancer Hospital
Phase 2 Completed
NCT03914417 2021-01-20
Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT00118313 2020-03-27
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
University of Virginia
Phase 1 Completed
NCT02385188 2020-01-02
Topical 5% Imiquimod Cream for Vulvar Paget's Disease
University Medical Center Nijmegen
Phase 3 Completed
NCT02276300 2019-11-20
HER2
Technical University of Munich
Phase 1 Completed
NCT00988559 2018-07-09
Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00504023 2018-06-06
Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT00821964 2018-01-02
Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
University of Washington
Phase 2 Completed
NCT01171469 2017-12-02
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00865644 2017-01-10
Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1
Massachusetts General Hospital
Phase 1 Completed
NCT01264731 2016-12-16
MEL53
University of Virginia
Phase 1 Completed
NCT00774787 2016-11-07
Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses
Rigel Dermatology
Phase 4 Completed
NCT00031759 2016-07-13
Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00899574 2015-12-07
Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases
NYU Langone Health
Phase 2 Completed
NCT00941811 2015-06-16
Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment
Medical University of Vienna
Phase 2 Completed
NCT00581425 2013-01-25
Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)
The University of Texas Health Science Center, Houston
Phase 4 Completed
NCT01161888 2012-06-20
LIMIT-1
University Hospital Birmingham NHS Foundation Trust
Phase 4 Completed
NCT01212562 2011-09-02
IMCX
University of Ioannina
Completed
NCT00204555 2011-09-01
Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma
University Hospital Tuebingen
Phase 4 Completed
NCT00941252 2011-01-24
ITIC
Medical University of Vienna
Phase 2/3 Completed
NCT00601016 2008-01-25
A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy
St. Justine's Hospital
Phase 2 Completed
NCT00175643 2006-05-09
Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses
University of British Columbia
Phase 3 Completed